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Abstract
Objectives To capture people’s beliefs about medicines reuse and to map the
determinants of intentions to reuse medicines in the future.
Methods Participants were recruited through an advert placed in the univer-
sity’s community newsletter reaching 15 000 households. Adults wishing to
participate were interviewed using convenience sampling, with recruitment con-
tinuing until data saturation. Participants were interviewed face-to-face by two
researchers using a semi-structured interview schedule based on the theory of
planned behaviour (TPB). Interview transcripts were analysed by thematic
analysis, with the themes classified according to the TPB. The University’s
research ethics committee approval was obtained.
Key findings Nineteen participants were interviewed. The potential economic
and environmental benefits of medicines reuse were juxtaposed with stability
and safety worries. Participants trusted pharmacists to quality-assure returned
medicines, but wondered if they had the time and storage space to dedicate
to medicines reuse. Environmentalists were seen as the main proponents of
medicines reuse with drug manufacturers, some taxpayers and parents seen
as the main opponents. The physical characteristics of reused medicines, and
quality assurance and logistics of reuse processes were seen to enable/ob-
struct engagement in medicines reuse. A working definition of medicines
reuse as a behaviour was developed.
Conclusions People could potentially agree to reuse medicines if their concerns
are addressed and the process is well defined and managed. This is a qualitative
study with a small number of participants meaning the results may not be gen-
eralisable. The themes generated will enable a structured questionnaire to be
developed for quantifying broader views.
Introduction
This article relates to the idea that unused prescribed
medication returned by one patient to a pharmacy can be
dispensed and therefore reused by another patient (‘medi-
cation reuse’) as a strategy for reducing medicinal waste
in the United Kingdom (UK). NHS England defines
medicinal waste as ‘Any substance or object the holder
discards, intends to discard or is required to discard’[1]
and the World Health Organisation further specifies
medicinal waste as ‘expired, unused, spilt and contami-
nated pharmaceutical products, drugs, vaccines and
sera’.[2] In the UK if a prescribed medication is no longer
being used, then conceptually that medication is
medicinal waste because it ought to be discarded rather
than, say, used by another patient. Medicines that have
been dispensed to patients, even if unused, are not cur-
rently allowed to re-enter the pharmaceutical supply
chain. One technical reason is uncertainty about the bio-
chemical integrity of medicines on leaving the formal dis-
tribution chain; for example, storage conditions in a
patient’s home may degrade the active ingredients. The
potential for counterfeit medicines to enter the pharma-
ceutical supply chain is another concern.
The financial cost of medicinal waste in the UK is esti-
mated as £300 million per year for prescribed
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medication.[3] However, monetary cost is only part of the
burden of medicinal waste. Environmental costs are also a
concern as the presence of pharmaceuticals in the envi-
ronment increases, with inappropriate disposal of medici-
nal waste potentially contributing. Research has found
that people are more likely to dispose of a range of
unwanted prescribed medicines in common refuse or
down the sink/toilet than return these to pharmacies for
correct disposal.[4,5] The environmental burden is not
inconsequential in that other studies have documented
the possible emergence of antibiotic resistance in wastew-
ater.[6] Prescribed medicinal waste can also impact nega-
tively on the environment through the ‘carbon footprint’.
Therefore logically, reducing medicinal waste relating to
unused prescribed medicines could impact on environ-
mental as well as financial costs.[7,8]
NHS England categorises prescribed medication waste
as non-adherence behaviours, preventable causes (e.g.
patient stockpiles) and non-preventable causes (e.g.
patient dies, recovers or treatment is changed).[1] To
reduce medicinal waste, one approach is to prevent waste
in the first place. Preventing waste is at the top of the
Waste Hierarchy, a grading system which ‘ranks waste
management options according to what is best for the
environment’, with ‘prepare for reuse’, ‘recycle’, ‘other
recovery’ and ‘disposal’ following ‘prevention’ in decreas-
ing order of preference.[9] Interventions that try to prevent
medicinal waste are not always effective and paradoxically,
the most common causes of medicinal waste are non-pre-
ventable.[10] Reuse and recycle remain largely unexplored
because unused medicines are not currently permitted to
be reused in the UK. An inhaler recycling scheme has
been trialled in Brighton, but this focussed on collecting
and recycling the inhaler device rather than recovering the
medicinal product contained in the inhaler canister.[11]
Medicines returned to a pharmacy are automatically con-
sidered to be waste that requires appropriate disposal.
Therefore, what normally takes place in community phar-
macy practice sits at the foot of the Waste Hierarchy. Yet,
anecdotally patients returning their medicines to pharma-
cies often voice a wish for these to be reused by others.
In fact, an NHS sustainability survey carried out by Ipsos
MORI in 2011 reported half of the respondents as likely
to accept re-issued medicines returned to pharmacies.[12]
A formal, quality-assured system for collecting and
reusing unused prescribed medicines could provide an
effective solution for the problem of medicinal waste in
the UK because it has the potential to address both the
preventable and non-preventable causes of medicinal
waste, which other management options cannot address.
There is precedence of medication reuse in other coun-
tries. For example, in the United States unused medicines
are collected and redistributed to patients who are less
able to afford the cost of medication.[13] Because the
implementation of medicines reuse in the UK would rely
heavily on people’s uptake of this idea, we have set out to
develop an understanding of what the public thinks about
this concept. To date, no formal research study has exam-
ined the general public’s views about and openness to the
idea of medicines reuse, although one study does exist
that focuses on pharmacists’ views.[14] The aim of the
current research was to capture people’s beliefs about
medicines reuse and to map the determinants of people’s
intentions to take part in medicines reuse behaviour. The
research question was ‘what are the behavioural determi-
nants of medicines reuse?’ The objectives were to define
medicines reuse as a behaviour and identify beliefs about
this behaviour using qualitative interviews and the theory
of planned behaviour (TPB).[15,16]
Methods
Compliance with ethical standards
This study was approved by the University of Reading’s
Research Ethics Committee through the School Exemp-
tions process (reference number 30/15) on 6/5/2015.
Written consent from each participant was obtained
before the interviews.
Approach
The aim was to capture people’s beliefs about the idea of
reusing medicines and to identify the relevant behavioural
determinants within a health psychology paradigm. The-
matic analysis was carried out because it provides a way
of organising qualitative interview data in the form of
themes: recurrent topics, ideas or statements identified
across the corpus of data. Thematic analysis also allows
for these themes to be mapped against a theoretical
framework within a deductive approach.[17] The frame-
work of the TPB was used to identify the themes.
The TPB makes a distinction between behaviour and
behavioural intentions on the basis that what people
intend to do is more predictable than what they will actu-
ally do.[15] Accordingly, behavioural intentions are a func-
tion of three determinants: firstly, the person’s attitude in
terms of likely consequences of the behaviour (be-
havioural beliefs), that is the individual’s positive or nega-
tive evaluation of taking part in the behaviour, creating a
favourable or unfavourable attitude towards the behaviour;
secondly, the person’s beliefs about the normative expec-
tations of other people (normative beliefs), that is social
pressure to take part or not take part in the particular
behaviour, creating a perceived social pressure or subjective
norm; thirdly, the individual’s beliefs about the existence
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of factors that may enable or obstruct taking part in the
behaviour (control beliefs), that is whether the person has
control over the behaviour, creating a belief about per-
ceived behavioural control. The combination of these three
factors leads to the formation of an individual’s be-
havioural intention, which is thought to be the immediate
antecedent of the behaviour according to the TPB. With a
sufficient degree of actual control over the behaviour, the
model expects that people would carry out their inten-
tions when the opportunity arises (Figure 1).
Setting and participant recruitment
Participants were recruited in spring 2016 through an
advertisement placed in the university’s community
newsletter circulated biannually to local residents. The
university’s community newsletter is often used to recruit
participants to research projects because it reaches 15 000
local households. The advert used for this study sought
English-speaking adults with an interest in the concept of
medicine reuse and willingness to participate in a qualita-
tive study by attending an interview at the university
campus. Medicines reuse was defined as ‘the idea that
medication returned by one patient can be dispensed by a
pharmacist to another patient (instead of disposal as
waste – which is what currently takes place)’ – see
Appendix S1 for a copy of the advert. Participants either
contacted the research team directly or were introduced
to the research team via already-recruited participants via
email. A balanced number of men and women were inter-
viewed, and there was also good representation across dif-
ferent age bands meaning that recruitment continued
until data saturation using convenience sampling. Data
saturation was guided by an initial desired sample size
(n = 20) determined by PD and HA according to the
TPB methodology[15] which was modified down when no
additional themes were identified after interviewing the
15th participant.[18] After this time point, four more
people were interviewed but three additional people who
contacted the research team expressing an interest were
turned away.
Data collection
A semi-structured interview schedule based on the TPB
and focussing on behavioural beliefs, normative beliefs
and control beliefs in relation to medicines reuse was
constructed and used in the interviews (see Table S1).[15]
Fifteen participants were interviewed by the main author
who is an experienced researcher (PD) with another
author (HA) (a PhD student) in attendance, after which
the remaining four participants were interviewed by HA.
Written consent was obtained, and the interviews, which
lasted around 40 min, were audio-recorded. Participants
were recruited until no more new and significant concepts
emerged (i.e. sampling saturation).
Data analysis
Interviews were transcribed verbatim, password-protected
and anonymised/de-identified by ‘The Transcription
Agency’, a university-approved supplier. HA reviewed all
transcripts to confirm that names or other information
that might identify the participants had been removed, and
he also ensured data integrity by cross-checking the tran-
scripts against the interview recordings, in consultation
with PD. The interview transcripts were analysed manually,
and then the NVivo 10 software (QSR International Pty
Ltd. Version 10, 2012) was used to visualise theme connec-
tions and to construct the final thematic map. The the-
matic analysis process was carried out by HA according to
the six phases described by Braun and Clarke[17] and was
reviewed by PD. The recordings were read and re-read
before being coded and categorised according to the TPB
to define behavioural beliefs, normative beliefs and control
beliefs about the reuse of unused prescribed medicines.
Figure 1 Schematic representation of the theory of planned behaviour, adapted from Ajzen (2006)[15], showing the relationship between the
determinants of behaviour (copyright ©2006 Icek Ajzen).
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Results
From 22 participants who contacted the research team, a
total of 19 were recruited (11 female), including one cou-
ple who were interviewed jointly. Two participants were
British Asian, and 17 were White British. Participant age
groups were 40–49 (n = 3), 50–59 (n = 2), 60–69 (n = 8)
and >70 (n = 6).
Three major categories were identified and labelled:
‘Consequences of medicines reuse’ (relating to beha-
vioural beliefs), ‘Exemplar and anti-exemplar individuals
and groups’ (relating to normative beliefs) and ‘Expecta-
tions about returned medicines’ (relating to control
beliefs). The compositional structure of these categories is
described in Tables 1–3.
Participants interviewed in this study were generally in
favour of the idea of medicines reuse in that they felt the
NHS should move to a system whereby unused prescribed
medicines would be reused instead of being discarded.
This system of reusing prescribed medicines would not be
obligatory, with patients opting in or out, and the whole
process regulated to prevent misuse. The following quote
illustrates this point:
Medicine reuse should be regulated and monitored by
NHS to avoid the risk of having black market, this
include pharmacist selling the collected medicines
online, and also counterfeit medicines that patient
bought online should not put back the shelf (if
returned) and this will be assured during a quality
check by the pharmacist. (P17, female, >70 age group)
Consequences of medicines reuse
This category encapsulates participants’ understanding of
the advantages and disadvantages of medicines reuse if
ever implemented (see Table 1).
Potential advantages of medicines reuse
Both economic and environmental advantages of reusing
medicines were discussed. Some perceived that reusing
unused medicines would save money for the NHS and
reduce manufacturing costs by cutting medicinal waste.
The following quote exemplifies this point:
I would say the main advantage of reusing medici-
nes is saving on cost, in this country masses of
drugs are wasted. When you have been prescribed
something and did not need much of it, and then
you think what an awful waste? (P5, Male, 60–69
age group)
Table 1 The compositional structure of category 1 ‘Consequences
of medicines reuse’
Consequences of medicines reuse
Participants’ attitudes towards medicines reuse involved an evaluation
of the benefits and the risks associated with the distribution of
returned medicines to other patients:
Potential advantages of medicines reuse
A. Economic impact on the NHS
• Direct monetary savings for the NHS
• Reduction in manufacturing expenditure
• Cost-benefit of reusing cheaper medicines
B. Environmental effects
• Reduction in negative environmental effects of medicines disposed
inappropriately
• Reduction in the carbon footprint
Potential disadvantages of medicines reuse
A. Poor quality medication
• Temperature of storage
• Humidity of storage environment
• Cleanliness of the storage environment
B. Harmful medication
• Deliberate or malicious tampering with returned medicines
• Medicines as a source of infection if contaminated
C. Incorrect medication
• Errors introduced by patients
• Errors introduced by pharmacists
• Risk posed by accepting counterfeit medicines
Table 2 The compositional structure of category 2: ‘Exemplar and
anti-exemplar individuals and groups’
Exemplar and anti-exemplar individuals and groups
The groups of individuals or people whom the participants thought
would or would not engage with and approve of medicines reuse
Individuals or groups of people who might approve of
medicine reuse
A. The Green movement
• Spouses and partners, relatives and friends who ‘think green’
• Environmentalists
• The Green Party, the political organisation
B. The elderly
• Those with a dislike of waste and an affinity for frugality
Individuals or groups of people who might disapprove of
medicine reuse
A. Pharmaceutical companies
• Employees
• Beneficiaries
B. Taxpayers
• UK Taxpayers with a sense of entitlement
C. Vulnerable patients (those making a decision for them)
• Babies
• Children
D. The elderly
• Cautious individuals worried about safety
• Terminally ill patients
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In addition, medicines reuse was thought more applica-
ble for expensive medicines especially if logistical costs of
reuse processes were to be substantially higher than the
monetary value of cheaper medicines; logistical costs were
conceptualised in different ways. For example, if medici-
nes reuse processes could not happen in a pharmacy
because of competing priorities or lack of storage space, a
formal, costly system for collecting and despatching
unused medicines to, say, a clinical centre might be
needed; there technicians could work to check, repackage
and prepare the medicines for reuse, which would carry a
cost. The following quote illustrates the former point:
Generic medicines, maybe they are so cheap that a
packet of aspirin cost maybe 16p or something, but
maybe some of the more expensive medicines that is
definitely worth reusing. (P3, male, 40–49 age group)
Medicines reuse was thought to reduce the proportion
of medicines thrown into household bins and encourage
people to return unused medicines to a pharmacy, thus
helping reduce negative environmental effects arising from
medicines reaching landfill or the water supply. Some felt
knowing returned medicines were destined for disposal
under the current system acted as a disincentive for
returning unused medicines to a pharmacy. For example:
I think one of the reasons people put medicines
down the loo is because they know if they take the
medicine back to the pharmacist he is going to
destroy them anyway so they think, why I should
make the effort with this, pointless. They don’t
understand the damage they might be doing so I
think there would be an environmental benefit.
(P15, male, 50–59 age group)
Medicine reuse was thought to reduce the overall car-
bon footprint of medicines by impacting on manufactur-
ing and transport of new medicines. For example:
So what I’m describing I think are people who are
more aware, shall I say, of a bigger picture, they’re
not thinking just personally, they’re thinking what
can I do, does it save the environment, if one less
packet of pills has to be made that’s one less
energy, that’s less transport, it’s all the good rea-
sons, not just money. (P2, male, >70)
Potential disadvantages of medicines reuse
Participants identified a range of issues with reusing
medicines that had been in the hands of other people.
The proper storage of unused medicines in terms of the
temperature, humidity or cleanliness of the storage envi-
ronment was one concern. Linked to this was the impact
on the safety of unused medicines. Safety was conceptu-
alised as inadvertent contamination or deliberate tamper-
ing. For example:
I think the main issue of reusing medicines would
be the risk. I suppose some medications have to be
stored at certain temperatures, like insulin. Also
you would have to be assured that the medicine
had not been tampered with. (P4, female, 60–69
age group)
Table 3 The compositional structure of category 3: ‘Expectations
about returned medicines’
Expectations about returned medicines
Factors that may facilitate or impede the workability of medicines
reuse for individuals
Physical characteristics of returned medicines
A. Original packaging of the medicine
• Medicines sealed by the manufacturer potentially suitable to be
reused
• Medicines in blister packaging potentially suitable to be reused
B. Whether the packaging had been opened or not
• Only unopened and sealed medicines to be reused
• Medicines not sealed or with a broken seal not to be reused
C. Remaining shelf life of medication
• Medicines should have more than 6 months of shelf life if to be
reused
D. Pharmaceutical presentation (formulation) of the product
• Solid oral dosage forms potentially suitable to be reused
• Liquid, creams and gels, and injections not to be reused
The quality assurance of returned medicines
A. Storage conditions
• Temperature and humidity of storage environment and risk of
degraded product
• Cleanliness of the storage environment and risk of spread of infec-
tion
B. Tampered product
• Malicious damage to the product to be ruled out
• Accidental damage to the product to be ruled out
C. Counterfeit medicines
• Medicines bought from untrusted sources including online sources
not to be reused
The logistics of medicine reuse
A. Collection and redistribution of returned medicine ‘on-site’ within a
pharmacy setting
• Efficiency of system for returning medicines
• Space for collection, processing and storage of returned medicines
• Pharmacists’ time availability to conduct quality assurance of
returned medicines
B. Collection and redistribution of returned medicines ‘off-site’
• Collection spots within pharmacies
• Clinical centres responsible for processing medicines for reuse
• Pharmaceutical companies to be involved in funding and supporting
reuse processes
C. Incentives for taking part in medicines reuse
• Points reward system to encourage the return of medicines
• Discount on medicines to encourage the reuse of medicines
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In addition, the risk of medication errors was high-
lighted in terms of errors introduced by patients and the
risk of returning counterfeit medicines. The risk of errors
made by pharmacists was also a concern such as redis-
tributing the wrong medicine to a patient and accepting
counterfeit medicines. For example:
There could be a risk of medication error being
made, for example if somebody put a medication
back in the wrong box and returned it. There have
to be very strict rules on checking the returned
medicines. (P6, male, >70 age group)
Participants’ recognition of the advantages of medicines
reuse was juxtaposed with assertions about a need for
quality and safety assurances. Pharmacists were trusted to
carry out quality and safety checks, but participants wor-
ried whether pharmacists had the time to devote to such
assurances (detailed further in the section entitled ‘Expec-
tations about medicines reuse’).
Exemplar and anti-exemplar individuals and
groups
This category encapsulates participants’ understanding of
individuals or groups of people who would partake or
particularly engage with and promote medicines reuse
(exemplar individuals and groups) and those who would
not (anti-exemplar individuals and groups) if a scheme
were to be implemented in the future.
Individuals or group of people who might
approve of medicine reuse
Those subscribing to the ideology of the ‘Green move-
ment’ were considered to support medicines reuse, with
spouses and partners, relatives and friends who think
green, environmentalists and members of the Green Party,
identified as people who might encourage medicines
reuse. For example:
I think my husband and some friends, I think peo-
ple who thinks green would support it. I would
have thought most environmentalists would sup-
port it because the other things is, a lot of this stuff
does end up in the water somehow or other, and
affects wildlife. (P17, female, >70 age group)
Individuals or groups of people who might
disapprove of medicine reuse
Pharmaceutical companies and their employees (or others
with an interest in these companies) were considered
amongst the group that would disapprove of medicines
reuse because of a potential to reduce financial profits.
For example:
I wonder if people working in pharmaceuticals
would not frown upon it in some way if their profits
are being affected. (P11, female, 40–49 age group)
Long-standing taxpayers were another group who
might disapprove of medicines reuse because of a sense
of entitlement to receive ‘the genuine medicine’. For
example:
Getting access to the NHS services is at the cost of
the UK taxpayer. I think because it’s so ingrained in
this country, the NHS and the prescription process,
that people almost feel that it is now like an entitle-
ment to have the genuine medicine at a fixed cost,
and that kind of thing. (P1, female, 60–69 age group)
Participants on the whole believed that people, espe-
cially mothers, may not approve of medicines reuse for
their children, with babies particularly seen as a ‘very spe-
cial group’. For example:
I think mothers are probably very cautious for their
offspring, and wants the best for her child, there’s a
kind of feeling because it’s brand new, off the shelf,
it’s purer, it’s safer, there’s no element of risk’. (P2,
male, >70 age group)
Participants had contradicting thoughts regarding the
stance taken by ‘the elderly’. Some thought older people
would support reusing medicines because of a natural
aversion to waste stemming from experiencing shortages
around the Second World War; this was compared to a
younger generation who might dislike using ‘second-hand
medicines’. For example:
I think particularly amongst the older generation
would probably be more susceptible to saying, yeah
medicine reuse is good idea, because we were
brought up not to waste things. I do not know if
youngsters think about that kind of thing as much
because there is a surplus of everything these days
but there was not when we grew up so we don’t,
we still don’t waste things, we still mend things.
(P17, female, >70 age group)
I think older people, the make do and mend gener-
ation who experienced shortages after Second
World War, who are fast becoming rare and rarer.
(P14, male, 60–69 age group)
Others thought that the elderly might in fact disap-
prove of medicines reuse if they have a terminal illness or
might be more cautious and concerned about the safety
of returned medicines.
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Expectations about returned medicines
This category encapsulates participants’ understanding of
factors that may facilitate or impede the workability of
medicines reuse as a formal process and is expressed in
terms of the participants’ expectations about returned
medicines (see Table 3).
Physical characteristics of returned medicines
It was clear that not all returned medicines were consid-
ered as suitable for medicines reuse. There was general
agreement that reused medicines should be those origi-
nally packaged in sealed or in blister-pack containers, be
unopened, comprise of oral solid dosage forms only, be a
genuine medicine (not a counterfeit) and have more than
6 months of shelf-life remaining. In contrast, returned
medicines that have a broken seal, have been opened, liq-
uids and injectable medicines, controlled drugs, medicines
with <6 months of shelf-life remaining and medicines
obtained from mistrusted or online sources would be
excluded from the reuse process. For example:
I don’t think medicine in a liquid form can be
reused, someone might introduce something such as
foreign body. This apply to gel and cream which is
maybe easier to inject or get something in it, whereas
in a blister pack you can tell whether it is been tam-
pered with or not. (P7, female, 60–69 age group)
The quality assurance of returned medicines
In addition to physically checking returned medicines,
there should be stringent quality and safety checks by the
pharmacist, to confirm suitability for reuse. The checking
process would involve the pharmacist confirming storage
conditions and discounting any risk of product degrada-
tion, contamination or infection. The pharmacist would
check that the product had not been tampered with, mali-
ciously or accidentally, damaged, bought from an online
source, and was not a counterfeit. For example:
I would be quite happy to reuse medicines as long
as I know that the safeguards have been put in
place that the returned medicines has not been
tampered with. (P4, female, 60–69 age group)
The logistics of medicine reuse
The medicines reuse processes including the collection
and the redistribution of returned medicines were consid-
ered in depth by the participants. Medicines could poten-
tially be returned to pharmacies (community pharmacies,
pharmacies within the GP clinics and hospital pharma-
cies) and assessed ‘on-site’. Pharmacists were considered
to be the professional group qualified to quality assure
the suitability of returned medicines for reuse purposes.
Potential challenges to an on-site system were the phar-
macist’s availability for collecting and checking returned
medicines, space within a pharmacy to enable processing
and storage of returned medicines, and whether the pro-
cess of returning medicines would be slick and rapid for
patients (which was preferred to having to queue). For
example:
As all returned medicine have to be checked. So
this could be a disadvantage in terms of pharma-
cists’ time because they are very busy in chemists,
aren’t they? Very busy pharmacists’. (P17, female,
>70 age group)
Because of these challenges, some of the participants
proposed an alternative model whereby medicines would
be dropped off in a specified area within a pharmacy
without the need to speak to any staff. Those medicines
would be despatched to a clinical centre where a pharma-
cist or trained technician completes a quality check in an
‘off-site’ model. An additional idea was to repackage
returned medicines before returning them to pharmacies
for reuse. However, the costs associated with having an
off-site system were highlighted as potentially prohibitive.
Some participants thought that pharmaceutical companies
should be obliged to support medicines reuse processes
financially or even help in the repackaging process. For
example:
Medicines have labels on them, so one assumes that
if you gave them back to the pharmacy, for exam-
ple, he would then have to send them back to the
supplier, the supplier would have to send them
back to the manufacturer, the manufacturer would
then have to repackage them, and then they have to
come all the way back down the chain. (P12,
female, 60–69 age group)
Incentives were thought to encourage patients to return
unused medicines instead of unsafe disposal practices.
Incentives could include a points reward system to
encourage medicines return or a discount to be offered
on any medicines reused.
So pharmacist can probably say here we are Mr. X,
here is those returned tablet and they are 50 pence
instead of £1 or whatever it is. So that sort of thing.
(P14, male, 60–69 age group)
Accordingly, a working definition of medicines reuse as
a behaviour coalesced as:
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accepting prescribed medication with more than
6 months of shelf-life remaining that, as verified by
a pharmacist, had been kept untampered for less
than three months, under normal storage condi-
tions and in an original sealed blister pack, by
another patient before being returned to a commu-
nity pharmacy.
People taking part in medicines reuse behaviour were
seen as:
adult patients prescribed medication for a chronic
(not terminal) condition with the capacity to
consent.
Discussion
A working definition of medicines reuse as a behaviour was
produced. In addition, people’s ideas about the advantages
and disadvantages of medicines reuse, who might approve
or disapprove of medicines reuse, and factors that would
impede or facilitate medicines reuse were mapped system-
atically using thematic analysis. The principle findings were
the potential for medicines reuse to impact positively on
the deleterious economic and environmental impact of
medicines waste, juxtaposed against a range of stability and
safety risks identified with reusing returned medicines.
While participants had trust in pharmacists’ competence to
quality-assure returned medicines, they expressed concerns
about their availability and access to sufficient storage space
to support medicines reuse processes. Environmentalists
and the Green Party were seen as the main proponents of
medicines reuse behaviour with drug manufacturers and
beneficiaries, some taxpayers and those caring for children
seen as the main opponents – there were contradictory
views about the stance of the elderly. The physical charac-
teristics of reused medicines, and quality assurance and
logistics of medicines reuse processes were considered as
factors that enabled or obstructed engagement in medicines
reuse.
One of the strengths of the current study is the applica-
tion of thematic analysis to summarise key themes and to
formalise views that the general public hold about medici-
nes reuse, which had only been reported anecdotally and
to the authors’ knowledge not appropriately investigated
until now. Themes obtained in this study have defined
what people understand by medicines reuse behaviour as
well as behavioural, normative and control beliefs. These
are the domains that according to the TPB are relevant
for predicting whether people intend to reuse medi-
cines.[15] This psychologically driven approach is another
strength of the current study which provides a mechanism
for measuring people’s intentions to engage in medicines
reuse behaviour, with a further potential for this approach
to be useful in wanting to change people’s intentions in
the future. However, the views are not likely to be repre-
sentative of the general UK population, firstly because
thematic analysis was completed with a small sample of
19 participants and secondly, because the sample was a
self-selected subgroup of the local population who
responded to a call to discuss medicine reuse.
There has been little work carried out previously at
examining perceptions about medicines reuse in the UK,
apart from a study that examined whether pharmacists
from one Health Board in South East Wales could come
to some consensus on the barriers and potential solutions
towards medicines reuse.[14] The results showed that
pharmacists would be willing to redistribute medicines if
certain criteria were met such as being solid dosage forms
with a tamper evident seal. Our findings are in line with
this. Other criteria expressed by pharmacists[14] included
liability protection, guidance from the professional regula-
tor, that reused medicines must be supplied in new pack-
aging, that technologies would need to be developed to
indicate inappropriate storage and that there must be
public engagement on medicine redistribution. Our work
was completed independently of the above study[14] and
addresses the feasibility of medicines reuse from the per-
spective of the general public, without whose approval
medicines reuse could not become a reality.
The participants interviewed recognised the problem of
medicines waste and the potential for medicines reuse to
minimise waste in the future. However, in identifying
particular groups that might disapprove of medicines
reuse, this study highlights the need to take account of
vulnerable patient groups, and to address political chal-
lenges if medicines reuse were to become a reality. For
example, the stance of the Association of the British Phar-
maceutical Industry who represent the pharmaceutical
industry in the UK remains unexplored. In addition, the
participants expressed positive views about the involve-
ment of pharmacists in the medicines reuse process,
which needs to be explored by pharmacy funding, profes-
sional and regulatory bodies. Interestingly, the people in
this study commented only on financial incentives for
patients and not for pharmacists. An alternative model
not requiring community pharmacies to quality check
medicines for reuse was also suggested in this study,
which partly mimics the American medication collection
system.[13] However, US legislation dictates for ‘A state-
licensed pharmacist or pharmacy to be part of the verifi-
cation and distribution process’.[13] The logistic of
medicines reuse in the UK therefore needs to be further
explored. Concerns about tampering and counterfeit
medicines entering the medicines reuse supply chain
might be addressed when the European Union directive
© 2017 The Authors. International Journal of Pharmacy Practice
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on falsified medicinal products (2011/62/EU) comes into
force in the UK in 2019, since a supplementary Delegated
Regulation (EU2016/161) requires marketing authorisa-
tion holders to add tamper evidence and a unique identi-
fier to the outer packaging of medicinal products.[19] The
role of heat, light and moisture sensitive monitoring labels
as a means of addressing concerns about the degradation
of returned medicines during storage remains to be inves-
tigated. Resolving the logistics of medicines reuse in the
UK could also support the international work of charities
such as InterCare[20] that rely on donated medicines.
The next steps are to develop and test a formal ques-
tionnaire that can capture systematically nationwide views
of medicines reuse and people’s willingness to reuse
medicines in the future.
Conclusion
This study suggests that people could potentially agree to
reuse medicines that are returned to pharmacies if their
concerns about safety and quality of the returned medici-
nes are addressed, the physical characteristics of medicines
are satisfactory, and the medicines reuse process is well
defined and managed. This is a qualitative study with a
small number of participants recruited from one local
area in the UK meaning that the results are not necessar-
ily generalisable. The themes generated will enable a struc-
tured questionnaire to be developed for quantifying
broader nationwide views about medicines reuse and
people’s intention to reuse medicines in the future.
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